论文部分内容阅读
目的:探讨铜绿假单胞菌注射液应用于直肠癌新辅助放化疗中的临床疗效。方法:选取某院2015年1-12月就诊的直肠癌患者72例,将患者随机分为对照组和治疗组,每组各36例。对照组给予口服卡培他滨825 mg·m-2,每日2次,每周5天,连用5周,并接受盆腔放疗。治疗组在对照组基础上皮下注射铜绿假单胞菌注射液1.0mL,隔日一次,连用30次。观察2组的临床疗效,同时比较治疗前后2组患者的免疫功能指标和毒副反应。结果:治疗后,对照组、治疗组的客观有效率分别为61.1%和83.3%,2组比较差异有统计学意义(P<0.05)。治疗后,对照组的NK细胞减少、CD8+细胞增加,治疗组的CD3+、CD4+细胞增加;治疗后2组免疫指标比较差异具有统计学意义(P<0.05)。治疗后,治疗组的骨髓抑制发生率明显低于对照组(P<0.05),其他放化疗相关不良反应发生率2组间差别无统计学意义。结论:铜绿假单胞菌注射液应用于直肠癌新辅助治疗可以增加疗效,增强免疫应答,减轻骨髓抑制,具有很好的临床应用价值。
Objective: To investigate the clinical efficacy of Pseudomonas aeruginosa injection in neoadjuvant radiochemotherapy for rectal cancer. Methods: Seventy-two patients with rectal cancer treated in our hospital from January to December in 2015 were randomly divided into control group and treatment group, with 36 cases in each group. The control group was given capecitabine 825 mg · m-2 orally twice a day for 5 days for 5 weeks and received pelvic radiotherapy. The treatment group was subcutaneously injected with 1.0 mL Pseudomonas aeruginosa injection on the basis of the control group, once every other day for 30 times. The clinical efficacy of the two groups were observed, and the immune function and toxicity of the two groups before and after treatment were compared. Results: After treatment, the objective and effective rates of the control group and the treatment group were 61.1% and 83.3%, respectively. There was significant difference between the two groups (P <0.05). After treatment, the number of NK cells and CD8 + cells in the control group increased, and the levels of CD3 + and CD4 + cells in the treatment group increased. After treatment, the immune indexes of the two groups were significantly different (P <0.05). After treatment, the incidence of bone marrow suppression in the treatment group was significantly lower than that in the control group (P <0.05). There was no significant difference in the incidence of other chemotherapy-related adverse reactions between the two groups. Conclusion: The application of Pseudomonas aeruginosa injection in neoadjuvant therapy of rectal cancer can increase the curative effect, enhance the immune response and reduce the myelosuppression, which has a good clinical value.